Q2 2025 · —
Revenue$3.85M$3.85M no prior Q2 2024 on file+144.6% vs Q1 2025
Net Income-$12.88M-$12.88M no prior Q2 2024 on fileN/M vs Q1 2025
EPS Diluted-$0.75-$0.75 no prior Q2 2024 on fileN/M vs Q1 2025
Operating Income-$12,864,000—
Operating Cash Flowderived-$11,907,000—
Free Cash Flowderived-$12,173,000—
Margins · derived
Operating margin-334.4%
Net margin-334.8%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q2 2024 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Atrium Therapeutics, Inc. · CIK 2093101 · Engraved from SEC EDGAR